Drug Profile


Alternative Names: 28a-Glycine-28b-(S-nitroso-L-cysteinamide)-vasoactive intestinal octacosapeptide; VIP-Gly-Cys-NO

Latest Information Update: 05 Sep 2002

Price : $50

At a glance

  • Originator La Jolla Pharmaceutical Company; Nonindustrial sources
  • Class Neuropeptides
  • Mechanism of Action Nitric oxide stimulants; Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Male sexual dysfunction

Most Recent Events

  • 02 Nov 1999 New profile
  • 02 Nov 1999 Preclinical development for Male sexual dysfunction in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top